Asset Details
Do you wish to reserve the book?
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
Do you wish to request the book?
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
2010
Overview
The platelet-stimulating agent romiplostim was compared with standard interventions for chronic immune thrombocytopenic purpura. Patients given romiplostim had higher platelet counts, less treatment failure, fewer bleeding episodes, and better quality of life.
Immune thrombocytopenia is an autoimmune disease characterized by low platelet counts due to both increased platelet destruction and suboptimal platelet production.
1
After initial treatment with glucocorticoids or intravenous immune globulin or anti-D immune globulin, most adult patients require second-line medical therapy (e.g., azathioprine or rituximab) or surgical therapy (i.e., splenectomy).
2
However, most first- and second-line medical treatments are short-acting, have severe side effects, or are potentially toxic.
2
–
4
These problems can adversely affect the health and quality of life of patients.
Splenectomy is used to remove the major site of platelet destruction and increase the platelet count.
5
In approximately two . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Biological and medical sciences
/ Female
/ Glucocorticoids - therapeutic use
/ Hematologic and hematopoietic diseases
/ Humans
/ Male
/ Platelet diseases and coagulopathies
/ Purpura, Thrombocytopenic, Idiopathic - drug therapy
/ Purpura, Thrombocytopenic, Idiopathic - surgery
/ Receptors, Fc - administration & dosage
/ Receptors, Fc - therapeutic use
/ Recombinant Fusion Proteins - administration & dosage
/ Recombinant Fusion Proteins - adverse effects
/ Recombinant Fusion Proteins - therapeutic use
/ Thrombopoietin - administration & dosage
/ Thrombopoietin - adverse effects
